文献速递认知障碍与痴呆

比较PET与MRI生物标志物预测临床前阿尔茨海默病认知下降

Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease.
PubMed 文献 · Neurology · 2021-06-14

本研究纳入131名临床正常成人,比较结构MRI、FDG-PET和flortaucipir PET预测认知下降的能力。结果显示在高淀粉样蛋白参与者中,内嗅皮层FDG低代谢是认知下降的独立预测因子,联合高PiB与低内嗅FDG可减少3倍所需样本量。

要点

  • 内嗅皮层FDG低代谢独立预测临床前AD认知下降
  • 高PiB合并低内嗅FDG可减少3倍试验样本量
  • 内嗅皮层FTP也是独立预测因子

核心结论

  • 在临床前阿尔茨海默病中,内嗅皮层低代谢是后续认知下降的强独立预测因子,FDG可能有助于提高临床试验效能。

研究设计与样本

  • 前瞻性队列研究,分析哈佛老化脑研究中131名临床正常成人(52名女性,年龄73.98±8.29岁),平均随访3年。

主要发现

  • 在单独模型中,大多数生物标志物在高PiB参与者中与认知下降的关联比低PiB参与者更密切。
  • 包含所有生物标志物的向后逐步回归显示,仅新皮质PiB、内嗅FTP和内嗅FDG是后续认知下降的独立预测因子。
  • 功效分析显示,使用高PiB和低内嗅FDG作为入选标准,相比仅使用高PiB,可将假设试验所需参与者数量减少3倍。

临床怎么用

  • 临床前AD临床试验可考虑将内嗅皮层FDG低代谢作为富集标准以提高统计功效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare how structural MRI, fluorodeoxyglucose (FDG), and flortaucipir (FTP) PET signals predict cognitive decline in high-amyloid vs low-amyloid participants with the goal of determining which biomarker combination would result in the highest increase of statistical power for prevention trials. METHODS: In this prospective cohort study, we analyzed data from clinically normal adults from the Harvard Aging Brain Study with MRI, FDG, FTP, and Pittsburgh compound B (PiB)-PET acquired within a year and prospective cognitive evaluations over a mean 3-year follow-up. We focused analyses on predefined regions of interest: inferior temporal, isthmus cingulate, hippocampus, and entorhinal cortex. Cognition was assessed with the Preclinical Alzheimer's Cognitive Composite. We evaluated the association between biomarkers and cognitive decline using linear mixed-effect models with random intercepts and slopes, adjusting for demographics. We generated power curves simulating prevention trials. RESULTS: Data from 131 participants (52 women, age 73.98 ± 8.29 years) were analyzed in the study. In separate models, most biomarkers had a closer association with cognitive decline in the high-PiB compared to the low-PiB participants. A backward stepwise regression including all biomarkers demonstrated that only neocortical PiB, entorhinal FTP, and entorhinal FDG were independent predictors of subsequent cognitive decline. Power analyses revealed that using both high PiB and low entorhinal FDG as inclusion criteria reduced 3-fold the number of participants needed in a hypothetical trial compared to using only high PiB. DISCUSSION: In preclinical Alzheimer disease, entorhinal hypometabolism is a strong and independent predictor of subsequent cognitive decline, making FDG a potentially useful biomarker to increase power in clinical trials. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that in people with preclinical Alzheimer disease, entorhinal hypometabolism identified by FDG-PET is predictive of subsequent cognitive decline.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Mayblyum DV, Becker JA, Jacobs HIL, et al. Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. Neurology. 2021. PMID: 33952655. doi:10.1212/WNL.0000000000012108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。